Odyssey Therapeutics priced an upsized initial public offering at $18 per share to raise about $304 million in gross proceeds, following a prior attempt to go public that was paused earlier. The autoimmune- and inflammatory-focused company plans to trade under the ticker ODTX on the Nasdaq Capital Market after the offering closes. The IPO consists of 15.5 million shares with an additional concurrent private placement to affiliate investor TPG Life Sciences Innovations. Underwriters have a 30-day option for further shares. Odyssey said proceeds will fund clinical development of its lead RIPK2 inhibitor OD-001 for ulcerative colitis, including Phase 2 work as monotherapy and in combination with Takeda’s Entyvio. Odyssey also plans to move its preclinical SLC15A4 program into Phase 1/2a studies. Management highlighted internal discovery and development as the foundation for its pipeline, with additional backing from OrbiMed and SR One earlier in the company’s history.